Objective: Prostatic diseases are a major cause of morbidity and mortality. The need is to detect the disease early in its natural history and manage it aggressively. Prostate-specific antigen (PSA) is not very sensitive, thus other indices are being employed. Argyrophillic nucleolar organizer region (AgNOR) count is the proliferative index marker used in our study. Our main objective was to evaluate the role of AgNOR in prostatic lesions and to find a correlation between serum PSA and AgNOR counts. Patients and Methods: We evaluated 60 patients of prostate diseases over a year. The patients were classified as benign prostatic hyperplasia (BPH), prostatitis, or prostatic adenocarcinoma (Ca). Patients with suspicious areas or foci of prostatic intraepithelial neoplasia (PIN) on histology were subjected to a slide review. All slides were H&E and AgNOR stained. Results: The difference between the mean AgNOR counts of BPH and prostatitis was significant, as between BPH and PIN (p < 0.001). The difference between low- and high-grade PIN was also significant.Ca prostate showed a significant increase in AgNOR counts from benign diseases; and also between localized and metastatic carcinoma (p < 0.001). On finding a correlation between serum PSA values and AgNOR counts, they were significant for benign and carcinoma cases (p < 0.001), though not for PIN. Conclusions: Our study depicts the usefulness of AgNOR counts in the diagnosis of various prostatic diseases including the pre malignant PIN. The relation between serum PSA and AgNOR was highly significant for BPH and Ca prostate. Hence, AgNOR is an efficient adjunct to our diagnostic armamentarium leading to improved prognostication and management.

Keywords:
AgNOR, Benign prostatic hyperplasia, Carcinoma, Prostatic intraepithelial neoplasia, Prostate diseases, Proliferative index, Prognosis, Prostate-specific antigen
This content is only available via PDF.
© 2009 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.